NanoViricides,Inc. (OTCBB:NNVC) Breaks Trend with Minor Fall
Sooner or later, the good news would be spent for NanoViricides,Inc. (OTCMKTS:NNVC) as the new higher price is left to evaluation. Recently, NNVC received an “orphan drug” status from the FDA, which would translate into tax discounts and other subsidies. NNVC retreated to $1.28, losing 3% on dollar volumes a bit above $850,000. 
Without significant negative news, NNVC has all chances to drift sideways or even make sharper gains if press releases attract the attention of investors. Also, NNVC has the benefit of a revival of biopharmaceutical tickers, as several are trading among the most active.
For the last time, NNVC was promoted in a no-compensation email on July 18th, but the climb in price was delayed until the news for the upcoming dengue fever drug were announced. On the good side, selling volumes are still lower than buying, suggesting that for some, the time has come to sell, but there is not a mass exodus of investors.
And for those who wait for the longer term, this is how NNVC is equipped:
- $15.4 million cash
- $17.8 million total assets
- $7.7 million total liabilities
- $3.6 million quarterly net loss
- $36 million loss for 96 months
The pumpers, BeaconEquity and Penny Stock Shark, have not made any new selections since NNVC, and in the past were only sporadic posters for stocks that only made short-term sensations. With NNVC, these pumpers might certainly improve their record, given that at most they achieved choppy trades and loss of volumes soon after the promotional emails stopped. So this comparison shows that NNVC has enough self-propelled activity.
A previous pick, Dolat Ventures, Inc. (OTCMKTS:DOLV) is the perfect example of a ticker barely hobbling without the effect of a promotion. BeaconEquity was tempted to take part in a hotter promotion, that of OriginOil, Inc. (OTCMKTS:OOIL), a ticker that peaked and made a classical, highly damaging slide to a faction of its value.
If NNVC impresses you, keep in mind that success is less durable than failure among penny stocks, and plan your investments accordingly.
